Akums Drugs & Pharmaceuticals
AKUMSNSE

Akums Drugs & Pharmaceuticals

₹759.45-1.50 (0.20%)1D
1D
1W
1M
3M
6M
1Y
3Y
5Y
All
Create Stock SIPAutomate your investments in this
Overview
Technicals
News
Events

Performance

Today’s low
754.00
Today’s high
775.00
52 week low
409.30
52 week high
769.45
Open price
760.95
Previous close
760.95
Live volume
1,65,718
Lower circuit
684.90
Upper circuit
837.00

Fundamentals

Market Cap
₹11,978Cr
ROE
7.70%
P/E Ratio(TTM)
40.91
EPS(TTM)
18.60
P/B Ratio
3.61
Dividend Yield
0.38%
Industry P/E
37.01
Book Value
210.57
Debt to Equity
0.05
Face Value
2

Financial performance

Quarterly
Yearly
All Financials
JUN '26
Revenue (Cr)
₹1,197
+0.32%
Profit (Cr)
₹101
+24.15%
03006009001.2k
Jun '25
Sep '25
Dec '25
Mar '26
Jun '26
Revenue growthValue
1Y (TTM)+14%
3Y CAGR+6%
Profit growthValue
1Y (TTM)+56%
3Y CAGR+38%

About

Akums Drugs & Pharmaceuticals Limited is a contract manufacturing pharmaceutical company producing formulations for various therapies.;
CEO/MD
Sanjeev Jain
Founded in
2004
NSE symbol
AKUMS

Shareholding pattern

Jun '25
Sep '25
Dec '25
Mar '26
Jun '26
Shareholder details

Mutual Funds Invested (4)

Similar stocks

StockMkt price (1D)52 week performanceMarket capP/E ratioP/B ratio
₹22,799.00
-156.00 (0.68%)
L
    H
    29,446.7859.1615.72
    ₹213.37
    -0.82 (0.38%)
    L
      H
      28,510.82--3.49
      ₹1,581.10
      -17.80 (1.11%)
      L
        H
        18,324.73--3.14
        ₹453.30
        -10.65 (2.30%)
        L
          H
          17,760.68303.434.54
          Livesquawk
          Akums Drugs targets API segment to achieve monthly EBITDA positivity by Feb/Mar FY27. API segment expected to contribute positively to corporate from FY28.
          Livesquawk
          Akums secures Zambia order worth INR 240 crore, reflecting in H2 FY27. European business operations expected to commence in FY28.
          Livesquawk
          Akums expects domestic branded formulations to improve from Q3 FY27. International branded formulations segment projected to return to growth soon.
          Livesquawk
          Akums Drugs expects robust FY27 performance with strong CDMO growth. CDMO segment likely to see double-digit growth; Q2 growth in high teens.
          2026
          8
          Aug
          Result
          Release date

          3
          Jul
          Dividend
          Ex date
          ₹1.00
          per share

          For each share you hold, you will receive ₹1.00
          Dividend amount₹1.00 per share
          Dividend TypeFinal
          Ex Date3 Jul ‘26
          Record Date3 Jul ‘26
          Announcement date14 May ‘26

          3
          Jul
          Dividend
          Ex date
          ₹2.00
          per share

          For each share you hold, you will receive ₹2.00
          Dividend amount₹2.00 per share
          Dividend TypeSpecial
          Ex Date3 Jul ‘26
          Record Date3 Jul ‘26
          Announcement date14 May ‘26

          14
          May
          Dividend
          Announced
          ₹1.00
          per share

          For each share you hold, you will receive ₹1.00
          Dividend amount₹1.00 per share
          Dividend TypeFinal
          Ex Date3 Jul ‘26
          Record Date3 Jul ‘26
          Announcement date14 May ‘26

          14
          May
          Dividend
          Announced
          ₹2.00
          per share

          For each share you hold, you will receive ₹2.00
          Dividend amount₹2.00 per share
          Dividend TypeSpecial
          Ex Date3 Jul ‘26
          Record Date3 Jul ‘26
          Announcement date14 May ‘26
          14
          May
          Quarterly & Annual Result
          Release date
          13
          Feb
          Quarterly Result
          Release date
          2025
          13
          Nov
          Quarterly Result
          Release date
          8
          Aug
          Quarterly Result
          Release date
          Events calendar
          View upcoming events in other stocks